Evidence for the Risks and Consequences of Adolescent Cannabis Exposure

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 56, Issue 3, 2017, Pages 214-225

  Levine, Amir ^a   Clemenza, Kelly ^a   Rynn, Moira ^a,b   Lieberman, Jeffrey ^a,b  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

adolescent cannabis use; affect; cross sensitization; executive function; psychosis

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; RECREATIONAL DRUG;

ADOLESCENT BEHAVIOR; ADULTHOOD; AFFECT; ANXIETY; CANNABIS USE; COGNITION; CROSS ALLERGY; EXECUTIVE FUNCTION; HUMAN; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SUBSTANCE ABUSE; ADOLESCENT; ADULT; ANIMAL; CHEMICALLY INDUCED; COGNITIVE DEFECT; DRUG DEPENDENCE; EMOTIONAL DISORDER;

ADOLESCENT; ADULT; AFFECTIVE SYMPTOMS; ANIMALS; CANNABINOIDS; COGNITIVE DYSFUNCTION; HUMANS; MARIJUANA USE; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 85013167645     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2016.12.014     Document Type: Review

References (139)

1. 1 Vandrey, R., Johnson, M.W., Johnson, P.S., Khalil, M.A., Novel drugs of abuse: a snapshot of an evolving marketplace. Adolesc Psychiatry 3 (2013), 123–134.
2. 2 Sobesky, M., Gorgens, K., Cannabis and adolescents: exploring the substance misuse treatment provider experience in a climate of legalization. Int J Drug Policy 33 (2016), 66–74.
3. 3 Leyton, M., Legalizing marijuana. J Psychiatry Neurosci 41 (2016), 75–76.
4. 4 ArcView Market Research. The State of Legal Marijuana Markets. 2nd ed., 2014, Arcview Group, Oakland, CA.
5. 5 Degenhardt, L., Ferrari, A.J., Calabria, B., et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One, 8, 2013, e76635.
6. 6 Johnston, L., O'Malley, P.M., National Institute on Drug Abuse, University of Michigan, Institute for Social Research. Monitoring the Future: National Survey Results on Drug Use, 1975-2014. 2015, National Institute on Drug Abuse, U.S. Dept. of Health and Human Services, National Institutes of Health, Bethesda, MD.
7. 7 Wang, G.S., Le Lait, M.C., Deakyne, S.J., Bronstein, A.C., Bajaj, L., Roosevelt, G., Unintentional pediatric exposures to marijuana in Colorado, 2009-2015. JAMA Pediatr, 170, 2016, e160971.
8. 8 Tapert, S.F., Granholm, E., Leedy, N.G., Brown, S.A., Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsych Soc 8 (2002), 873–883.
9. 9 Lynskey, M.T., Heath, A.C., Bucholz, K.K., et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 289 (2003), 427–433.
10. 10 Silins, E., Horwood, L.J., Patton, G.C., et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 1 (2014), 286–293.
11. 11 Bechtold, J., Simpson, T., White, H.R., Pardini, D., Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychol Addict Behav 29 (2015), 552–563.
12. 12 Mokrysz, C., Landy, R., Gage, S.H., Munafo, M.R., Roiser, J.P., Curran, H.V., Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol 30 (2016), 159–168.
13. 13 Verweij, K.J.H., Zietsch, B.P., Lynskey, M.T., et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 105 (2010), 417–430.
14. 14 Agrawal, A., Lynskey, M.T., Hinrichs, A., et al. A genomewide association study of DSM-IV cannabis dependence. Addict Biol 16 (2011), 514–518.
15. 15 Stringer, S., Minică, C.C., Verweij, K.J.H., et al. Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Transl Psychiatry, 6, 2016, e769.
16. 16 Carey, C.E., Agrawal, A., Bucholz, K.K., et al. Associations between polygenic risk for psychiatric disorders and substance involvement. Front Genet, 7, 2016, 149.
17. 17 Power, R.A., Verweij, K.J.H., Zuhair, M., et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry 19 (2014), 1201–1204.
18. 18 Minica, C.C., Dolan, C.V., Hottenga, J.J., et al. Heritability, SNP- and gene-based analyses of cannabis use initiation and age at onset. Behav Genet 45 (2015), 503–513.
19. 19 Bogdan, R., Winstone, J.M., Agrawal, A., Genetic and environmental factors associated with cannabis involvement. Curr Addict Rep 3 (2016), 199–213.
20. 20 Dougherty, D.M., Mathias, C.W., Dawes, M.A., et al. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology 226 (2013), 307–319.
21. 21 Fried, P.A., Watkinson, B., Gray, R., Neurocognitive consequences of marihuana–a comparison with pre-drug performance. Neurotoxicol Teratol 27 (2005), 231–239.
22. 22 Tait, R.J., Mackinnon, A., Christensen, H., Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 106 (2011), 2195–2203.
23. 23 McHale, S., Hunt, N., Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol 23 (2008), 409–415.
24. 24 Crean, R.D., Crane, N.A., Mason, B.J., An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5 (2011), 1–8.
25. 25 Verdejo-Garcia, A., Rivas-Perez, C., Lopez-Torrecillas, F., Perez-Garcia, M., Differential impact of severity of drug use on frontal behavioral symptoms. Addict Behav 31 (2006), 1373–1382.
26. 26 Meier, M.H., Caspi, A., Ambler, A., et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S Am 109 (2012), E2657–E2664.
27. 27 Lyons, M.J., Bar, J.L., Panizzon, M.S., et al. Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med 34 (2004), 1239–1250.
28. 28 Ehrenreich, H., Rinn, T., Kunert, H.J., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142 (1999), 295–301.
29. 29 Tapert, S.F., Granholm, E., Leedy, N.G., Brown, S.A., Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc 8 (2002), 873–883.
30. 30 Pope, H.G. Jr., Gruber, A.J., Hudson, J.I., Cohane, G., Huestis, M.A., Yurgelun-Todd, D., Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 69 (2003), 303–310.
31. 31 Fontes, M.A., Bolla, K.I., Cunha, P.J., et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198 (2011), 442–447.
32. 32 Pope, H.G., Gruber, A.J., Hudson, J.I., Cohane, G., Huestis, M.A., Yurgelun-Todd, D., Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 69 (2003), 303–310.
33. 33 Crane, N.A., Schuster, R.M., Mermelstein, R.J., Gonzalez, R., Neuropsychological sex differences associated with age of initiated use among young adult cannabis users. J Clin Exp Neuropsychol 37 (2015), 389–401.
34. 34 Rogeberg, O., Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. Proc Natl Acad Sci U S A 110 (2013), 4251–4254.
35. 35 Daly, M., Personality may explain the association between cannabis use and neuropsychological impairment. Proc Natl Acad Sci U S A, 110, 2013, E979.
36. 36 Jackson, N.J., Isen, J.D., Khoddam, R., et al. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci U S A 113 (2016), E500–E508.
37. 37 Filbey, F.M., McQueeny, T., DeWitt, S.J., Mishra, V., Preliminary findings demonstrating latent effects of early adolescent marijuana use onset on cortical architecture. Dev Cogn Neurosci 16 (2015), 16–22.
38. 38 Abdullaev, Y., Posner, M.I., Nunnally, R., Dishion, T.J., Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res 215 (2010), 45–57.
39. 39 Gruber, S.A., Dahlgren, M.K., Sagar, K.A., Gonenc, A., Lukas, S.E., Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology 231 (2014), 1455–1465.
40. 40 Becker, B., Wagner, D., Gouzoulis-Mayfrank, E., Spuentrup, E., Daumann, J., The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuro-psychopharmacol Biol Psychiatry 34 (2010), 837–845.
41. 41 Delisi, L.E., Bertisch, H.C., Szulc, K.U., et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm Reduct J, 3, 2006, 17.
42. 42 Renard, J., Vitalis, T., Rame, M., et al. Chronic cannabinoid exposure during adolescence leads to long-term structural and functional changes in the prefrontal cortex. Eur Neuropsychopharmacol 26 (2016), 55–64.
43. 43 Rubino, T., Prini, P., Piscitelli, F., et al. Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis 73 (2015), 60–69.
44. 44 O'Shea, M., Singh, M.E., McGregor, I.S., Mallet, P.E., Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18 (2004), 502–508.
45. 45 O'Shea, M., McGregor, I.S., Mallet, P.E., Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20 (2006), 611–621.
46. 46 Quinn, H.R., Matsumoto, I., Callaghan, P.D., et al. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33 (2008), 1113–1126.
47. 47 Schneider, M., Koch, M., Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003), 1760–1769.
48. 48 Lee, T.T.Y., Gorzalka, B.B., Evidence for a role of adolescent endocannabinoid signaling in regulating HPA axis stress responsivity and emotional behavior development. Int Rev Neurobiol 125 (2015), 49–84.
49. 49 Wade, T.J., Pevalin, D.J., Adolescent delinquency and health. Can J Criminol 47 (2005), 619–654.
50. 50 Brook, J.S., Rosen, Z., Brook, D.W., The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist 13 (2001), 35–40.
51. 51 Patton, G.C., Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., Hall, W., Cannabis use and mental health in young people: cohort study. BMJ, 325, 2002, 1195.
52. 52 de Graaf, R., Radovanovic, M., van Laar, M., et al. Early cannabis use and estimated risk of later onset of depression spells: epidemiologic evidence from the population-based World Health Organization World Mental Health Survey Initiative. Am J Epidemiol 172 (2010), 149–159.
53. 53 van Laar, M., van Dorsselaer, S., Monshouwer, K., de Graaf, R., Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population?. Addiction 102 (2007), 1251–1260.
54. 54 Degenhardt, L., Coffey, C., Romaniuk, H., et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 108 (2013), 124–133.
55. 55 Hayatbakhsh, M.R., Najman, J.M., Jamrozik, K., Mamun, A.A., Alati, R., Bor, W., Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46 (2007), 408–417.
56. 56 Green, B.E., Ritter, C., Marijuana use and depression. J Health Soc Behav 41 (2000), 40–49.
57. 57 Moore, T.H.M., Zammit, S., Lingford-Hughes, A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (2007), 319–328.
58. 58 Womack, S.R., Shaw, D.S., Weaver, C.M., Forbes, E.E., Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men. J Stud Alcohol Drugs 77 (2016), 287–297.
59. 59 Degenhardt, L., Hall, W., Lynskey, M., Exploring the association between cannabis use and depression. Addiction 98 (2003), 1493–1504.
60. 60 van Ours, J.C., Williams, J., Fergusson, D., Horwood, L.J., Cannabis use and suicidal ideation. J Health Econ 32 (2013), 524–537.
61. 61 Lynskey, M.T., Glowinski, A.L., Todorov, A.A., et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry 61 (2004), 1026–1032.
62. 62 Butterworth, P., Slade, T., Degenhardt, L., Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being. Drug Alcohol Rev 33 (2014), 555–564.
63. 63 Biscaia, M., Marin, S., Fernandez, B., et al. Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology 170 (2003), 301–308.
64. 64 Rubino, T., Vigano, D., Realini, N., et al. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33 (2008), 2760–2771.
65. 65 Zamberletti, E., Beggiato, S., Steardo, L. Jr., et al. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 63 (2014), 35–47.
66. 66 Arendt, M., Rosenberg, R., Foldager, L., Perto, G., Munk-Jorgensen, P., Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 187 (2005), 510–515.
67. 67 Niemi-Pynttari, J.A., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K., Pirkola, S.P., Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 74 (2013), e94–e99.
68. 68 Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., Moffitt, T.E., Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325 (2002), 1212–1213.
69. 69 Miller, P., Lawrie, S.M., Hodges, A., Clafferty, R., Cosway, R., Johnstone, E.C., Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 36 (2001), 338–342.
70. 70 van Os, J., Bak, M., Hanssen, M., Bijl, R.V., de Graaf, R., Verdoux, H., Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156 (2002), 319–327.
71. 71 Galvez-Buccollini, J.A., Proal, A.C., Tomaselli, V., et al. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res 139 (2012), 157–160.
72. 72 Leroy, S., Griffon, N., Bourdel, M.C., Olie, J.P., Poirier, M.F., Krebs, M.O., Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105 (2001), 749–752.
73. 73 Ujike, H., Takaki, M., Nakata, K., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7 (2002), 515–518.
74. 74 Caspi, A., Moffitt, T.E., Cannon, M., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57 (2005), 1117–1127.
75. 75 Alemany, S., Arias, B., Fatjo-Vilas, M., et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 129 (2014), 54–62.
76. 76 Vinkers, C.H., Van Gastel, W.A., Schubart, C.D., et al. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr Res 150 (2013), 303–311.
77. 77 van Winkel, R., van Beveren, N.J., Simons, C., Genetic, R., Risk and Outcome of Psychosis (GROUP) Investigators. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacol 36 (2011), 2529–2537.
78. 78 Di Forti, M., Iyegbe, C., Sallis, H., et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72 (2012), 811–816.
79. 79 Decoster, J., van Os, J., Kenis, G., et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 156B (2011), 363–369.
80. 80 Pelayo-Teran, J.M., Suarez-Pinilla, P., Chadi, N., Crespo-Facorro, B., Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Design 18 (2012), 5024–5035.
81. 81 French, L., Gray, C., Leonard, G., et al. Early cannabis use, polygenic risk score for schizophrenia, and brain maturation in adolescence. JAMA Psychiatry 72 (2015), 1002–1011.
82. 82 Llorente-Berzal, A., Fuentes, S., Gagliano, H., et al. Sex-dependent effects of maternal deprivation and adolescent cannabinoid treatment on adult rat behaviour. Addict Biol 16 (2011), 624–637.
83. 83 O'Tuathaigh, C.M., Clarke, G., Walsh, J., et al. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol 15 (2012), 1331–1342.
84. 84 Degenhardt, L., Hall, W., Lynskey, M., Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71 (2003), 37–48.
85. 85 Hunt, G.E., Bergen, J., Bashir, M., Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 54 (2002), 253–264.
86. 86 Lewis, S.W., Tarrier, N., Drake, R.J., Integrating non-drug treatments in early schizophrenia. Br J Psychiatry Suppl 48 (2005), s65–s71.
87. 87 Wade, D., Harrigan, S., Edwards, J., Burgess, P.M., Whelan, G., McGorry, P.D., Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 81 (2006), 145–150.
88. 88 Kandel, D., Faust, R., Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiatry 32 (1975), 923–932.
89. 89 Mayet, A., Legleye, S., Falissard, B., Chau, N., Cannabis use stages as predictors of subsequent initiation with other illicit drugs among French adolescents: use of a multi-state model. Addict Behav 37 (2012), 160–166.
90. 90 Badiani, A., Boden, J.M., De Pirro, S., Fergusson, D.M., Horwood, L.J., Harold, G.T., Tobacco smoking and cannabis use in a longitudinal birth cohort: evidence of reciprocal causal relationships. Drug Alcohol Depend 150 (2015), 69–76.
91. 91 Patton, G.C., Coffey, C., Carlin, J.B., Sawyer, S.M., Lynskey, M., Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100 (2005), 1518–1525.
92. 92 Reilly, D., Didcott, P., Swift, W., Hall, W., Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93 (1998), 837–846.
93. 93 Fergusson, D.M., Horwood, L.J., Does cannabis use encourage other forms of illicit drug use?. Addiction 95 (2000), 505–520.
94. 94 Fergusson, D.M., Boden, J.M., Horwood, L.J., Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 101 (2006), 556–569.
95. 95 Stuart, E.A., Green, K.M., Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes. Dev Psychol 44 (2008), 395–406.
96. 96 Shedler, J., Block, J., Adolescent drug use and psychological health. A longitudinal inquiry. Am Psychol 45 (1990), 612–630.
97. 97 Newcomb, M.D., Bentler, P.M., Consequences of Adolescent Drug Use: Impact on the Lives of Young Adults. 1988, Sage Publications, Newbury Park, CA.
98. 98 Agrawal, A., Neale, M.C., Prescott, C.A., Kendler, K.S., A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 34 (2004), 1227–1237.
99. 99 Fergusson, D.M., Boden, J.M., Cannabis use and later life outcomes. Addiction 103 (2008), 969–976 discussion 977-968.
100. 100 Levine, A., Huang, Y.Y., Drisaldi, B., et al. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 3 (2011), 107–109.
101. 101 Tomasiewicz, H.C., Jacobs, M.M., Wilkinson, M.B., Wilson, S.P., Nestler, E.J., Hurd, Y.L., Proenkephalin mediates the enduring effects of adolescent cannabis exposure associated with adult opiate vulnerability. Biol Psychiatry 72 (2012), 803–810.
102. 102 Ellgren, M., Spano, S.M., Hurd, Y.L., Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32 (2007), 607–615.
103. 103 Cadoni, C., Simola, N., Espa, E., Fenu, S., Di Chiara, G., Strain dependence of adolescent cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol 20 (2015), 132–142.
104. 104 Jarbe, T.U., LeMay, B.J., Halikhedkar, A., et al. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats. Psychopharmacology 231 (2014), 489–500.
105. 105 De Vry, J., Jentzsch, K.R., Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 14 (2003), 471–476.
106. 106 Laviola, G., Macri, S., Morley-Fletcher, S., Adriani, W., Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neurosci Biobehav Rev 27 (2003), 19–31.
107. 107 Keeley, R.J., Trow, J., McDonald, R.J., Strain and sex differences in puberty onset and the effects of THC administration on weight gain and brain volumes. Neuroscience 305 (2015), 328–342.
108. 108 Fehr, K.A., Kalant, H., LeBlanc, A.E., Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science 192 (1976), 1249–1251.
109. 109 Stiglick, A., Kalant, H., Learning impairment in the radial-arm maze following prolonged cannabis treatment in rats. Psychopharmacology 77 (1982), 117–123.
110. 110 Stiglick, A., Llewellyn, M.E., Kalant, H., Residual effects of prolonged cannabis treatment on shuttle-box avoidance in the rat. Psychopharmacology 84 (1984), 476–479.
111. 111 Stiglick, A., Kalant, H., Residual effects of chronic cannabis treatment on behavior in mature rats. Psychopharmacology 85 (1985), 436–439.
112. 112 Cha, Y.M., White, A.M., Kuhn, C.M., Wilson, W.A., Swartzwelder, H.S., Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav 83 (2006), 448–455.
113. 113 Cha, Y.M., Jones, K.H., Kuhn, C.M., Wilson, W.A., Swartzwelder, H.S., Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol 18 (2007), 563–569.
114. 114 Lee, T.T., Wainwright, S.R., Hill, M.N., Galea, L.A., Gorzalka, B.B., Sex, drugs, and adult neurogenesis: sex-dependent effects of escalating adolescent cannabinoid exposure on adult hippocampal neurogenesis, stress reactivity, and amphetamine sensitization. Hippocampus 24 (2014), 280–292.
115. 115 Malone, D.T., Hill, M.N., Rubino, T., Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 160 (2010), 511–522.
116. 116 Morales-Munoz, I., Jurado-Barba, R., Ponce, G., et al. Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res 220 (2014), 535–540.
117. 117 Schneider, M., Drews, E., Koch, M., Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav Pharmacol 16 (2005), 447–454.
118. 118 Wegener, N., Koch, M., Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 1253 (2009), 81–91.
119. 119 Gleason, K.A., Birnbaum, S.G., Shukla, A., Ghose, S., Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry, 2, 2012, e199.
120. 120 Bortolato, M., Bini, V., Frau, R., et al. Juvenile cannabinoid treatment induces frontostriatal gliogenesis in Lewis rats. Eur Neuropsychopharmacol 24 (2014), 974–985.
121. 121 Long, L.E., Chesworth, R., Huang, X.F., McGregor, I.S., Arnold, J.C., Karl, T., Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol 16 (2013), 163–175.
122. 122 Llorente-Berzal, A., Puighermanal, E., Burokas, A., et al. Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption. PLoS One, 8, 2013, e78386.
123. 123 Guidotti, A., Auta, J., Davis, J.M., et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology 180 (2005), 191–205.
124. 124 Cass, D.K., Flores-Barrera, E., Thomases, D.R., Vital, W.F., Caballero, A., Tseng, K.Y., CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry 19 (2014), 536–543.
125. 125 Spano, M.S., Fadda, P., Fratta, W., Fattore, L., Cannabinoid-opioid interactions in drug discrimination and self-administration: effect of maternal, postnatal, adolescent and adult exposure to the drugs. Curr Drug Targets 11 (2010), 450–461.
126. 126 Pistis, M., Perra, S., Pillolla, G., Melis, M., Muntoni, A.L., Gessa, G.L., Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56 (2004), 86–94.
127. 127 Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., Seltzman, H.H., Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285 (1998), 285–292.
128. 128 De Vry, J., Jentzsch, K.R., Kuhl, E., Eckel, G., Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15 (2004), 1–12.
129. 129 Naef, M., Russmann, S., Petersen-Felix, S., Brenneisen, R., Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 93 (2004), 1176–1184.
130. 130 Manwell, L.A., Mallet, P.E., Comparative effects of pulmonary and parenteral Delta(9)-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats. Psychopharmacology 232 (2015), 1655–1665.
131. 131 Marshell, R., Kearney-Ramos, T., Brents, L.K., et al. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Delta9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav 124 (2014), 40–47.
132. 132 Pomahacova, B., Van der Kooy, F., Verpoorte, R., Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 21 (2009), 1108–1112.
133. 133 Hazekamp, A., Fischedick, J.T., Cannabis–from cultivar to chemovar. Drug Test Anal 4 (2012), 660–667.
134. 134 Elsohly, M.A., Slade, D., Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78 (2005), 539–548.
135. 135 Russo, E., Guy, G.W., A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66 (2006), 234–246.
136. 136 Atakan, Z., Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2 (2012), 241–254.
137. 137 Brunt, T.M., van Genugten, M., Honer-Snoeken, K., van de Velde, M.J., Niesink, R.J., Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. J Clin Psychopharmacol 34 (2014), 344–349.
138. 138 Blevins, C.E., Banes, K.E., Stephens, R.S., Walker, D.D., Roffman, R.A., A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: characteristics and treatment outcomes. Addict Behav 63 (2016), 114–119.
139. 139 Gunderson, E.W., Haughey, H.M., Ait-Daoud, N., Joshi, A.S., Hart, C.L., “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21 (2012), 320–326.